【摘要】：目的： 本課題屬于軟堅(jiān)消癭顆粒的長(zhǎng)期毒性研究�；谇捌谒帉W(xué)實(shí)驗(yàn)探明軟堅(jiān)消癭顆粒的制備工藝、質(zhì)量標(biāo)準(zhǔn)及穩(wěn)定性、急性毒性試驗(yàn)和藥效學(xué)的基礎(chǔ)上，本次試驗(yàn)主要觀察該制劑對(duì)大鼠血液學(xué)、血液生化學(xué)指標(biāo)是否出現(xiàn)長(zhǎng)期毒性反應(yīng)，以此預(yù)測(cè)軟堅(jiān)消癭顆�？赡芤鸬呐R床不良反應(yīng)，包括不良反應(yīng)的性質(zhì)、程度、劑量-反應(yīng)和時(shí)間-反應(yīng)關(guān)系以及可逆性等；推測(cè)軟堅(jiān)消癭顆粒重復(fù)給藥的臨床毒性靶器官或靶組織；預(yù)測(cè)臨床試驗(yàn)的起始劑量和重復(fù)用藥的安全劑量范圍；提示臨床試驗(yàn)中需要重點(diǎn)監(jiān)測(cè)的指標(biāo)；為臨床中的解毒或解救措施提供參考信息。最終為新藥的研發(fā)提供更可靠的理論依據(jù)，為軟堅(jiān)消癭顆粒進(jìn)入臨床試驗(yàn)階段奠定基礎(chǔ)。 材料與方法： 采用SPF級(jí)、體重為120±20g的SD雌雄大鼠各120只，隨機(jī)分為對(duì)照組、低劑量組、中劑量組、高劑量組各60只，灌胃給予指定劑量的軟堅(jiān)消癭顆粒處方的提取物。每日灌胃2次，間隔8小時(shí)。分別于給藥后3個(gè)月（中期）、6個(gè)月（末期）各隨機(jī)抽取每組1/3數(shù)量的大鼠給予25%烏拉坦腹腔注射麻醉，取動(dòng)脈血進(jìn)行血液學(xué)、血液生化學(xué) 檢測(cè)。6個(gè)半月（恢復(fù)期）將剩余大鼠全部取動(dòng)脈血做檢測(cè)。結(jié)果： 1各組雌、雄性大鼠在試驗(yàn)期間外觀體征、行為活動(dòng)均無(wú)異常變化。 2各組大鼠的體重與攝食量均呈每周遞增趨勢(shì)增加。給藥期間軟堅(jiān)消癭顆粒中、高劑量組大鼠的體重、攝食量分別與生理鹽水對(duì)照組比較有顯著性差異（P＜0.05），考慮與灌胃給藥有關(guān)。 3血液學(xué)指標(biāo)中，中期低、中劑量組雄性大鼠的WBC、LYMPH、RBC與對(duì)照組比較有顯著性差異（P＜0.05），中劑量組的MON與對(duì)照組比較有顯著性差異（P＜0.05），低劑量組的MCV、MCH、RC、雌性大鼠的PT與對(duì)照組比較有顯著性差異（P＜0.05）。末期中劑量組雄性大鼠的RBC，，高劑量組雌性大鼠的WBC、MCV分別與對(duì)照組比較有顯著性差異（P＜0.05）�；謴�(fù)期中劑量組雄性大鼠的HGB、高劑量組的MCH分別與對(duì)照組比較有顯著性差異（P＜0.05），低、中、高劑量組的RBC與對(duì)照組比較有顯著性差異（P＜0.05）；中、高劑量組雌性大鼠的Gran、RDW與對(duì)照組比較均有顯著性差異（P＜0.05），高劑量組的MCV、MCH、PLT分別與對(duì)照組比較均有顯著性差異（P＜0.05），其余結(jié)果顯示均無(wú)顯著性差異（P＞0.05）。 4血液生化指標(biāo)中，中期低、中、高劑量組雄性大鼠的ALT、AST、雌性大鼠的Cr分別與對(duì)照組比較有顯著性差異（P＜0.05）。末期中劑量組的TP、ALB與對(duì)照組比較有顯著性差異（P＜0.05）�；謴�(fù)期中劑量組雌性大鼠的TP、ALB對(duì)照組比較有顯著性差異（P＜0.05），中、高劑量組的CR與對(duì)照組比較有顯著性差異（P＜0.05）。各組雌、雄性大鼠的GLU均高于正常值范圍。其余結(jié)果顯示均無(wú)顯著性差異（P＞0.05）。 結(jié)論： 軟堅(jiān)消癭顆粒按試驗(yàn)的劑量服用時(shí)安全，對(duì)大鼠的血常規(guī)、肝腎等功能均無(wú)明顯的毒副作用。可投入下一步的臨床試驗(yàn)階段。
[Abstract]:Objective: to study the long-term toxicity of Ruanjian Xiaoying granules. Based on the previous pharmacological experiments, the preparation process, quality standard and stability, acute toxicity test and pharmacodynamics of Ruangjian Xiaoying granule, this experiment mainly observed the effect of the preparation on rat hematology. Whether there is long-term toxic reaction in blood biochemistry index, so as to predict the possible clinical adverse reactions caused by Ruangjian Xiaoying granule, including the nature, degree, dose-response, time-response relationship and reversibility of the adverse reactions. The clinical toxic target organ or target tissue of repeated administration of Ruangjian Xiaoying granule was inferred, the initial dose of clinical trial and the safe dose range of repeated administration were predicted, and the key monitoring indexes in clinical trial were suggested. To provide reference information for clinical detoxification or rescue measures. Finally, it provides a more reliable theoretical basis for the research and development of new drugs, and lays the foundation for Ruanjian Xiaoying granules to enter the clinical trial stage. Materials and methods: 120 male and female SD rats of SPF grade, weight 120 鹵20g, were randomly divided into control group, low dose group, middle dose group and high dose group (60 rats). Two times a day, 8 hours interval. At the end of 6 months and 3 months after administration, rats in each group were randomly selected for intraperitoneal injection of 25% uratan, and arterial blood was taken for hematology, and a third of the rats in each group were given intraperitoneal anaesthesia. Blood biochemical examination. 6 and a half months (convalescence) the remaining rats were collected for arterial blood test. Results: 1 there were no abnormal changes in appearance signs and behavioral activities of female and male rats in each group during the experiment. 2 the body weight and food intake of rats in each group increased weekly. There were significant differences in body weight and food intake between the high dose group and the saline control group (P < 0.05). 3There was a significant difference in WBC,LYMPH,RBC between the middle dose group and the control group (P < 0. 05), and the difference between the middle dose group and the control group (P < 0. 05), and the difference between the middle dose group and the control group was significant (P < 0. 05), and there was a significant difference between the middle dose group and the control group (P < 0. 05). The PT of MCV,MCH,RC, female rats in low dose group was significantly different from that of control group (P < 0. 05). The WBC,MCV of female rats in RBC, high dose group was significantly higher than that in control group (P < 0. 05). There was significant difference in MCH between the high dose group and the control group in the middle dose group and the control group in the recovery period (P < 0. 05). The RBC in the middle and high dose group was significantly higher than that in the control group (P < 0. 05), while that in the middle and high dose group was significantly higher than that in the control group (P < 0. 05). The Gran,RDW of female rats in high dose group was significantly different from that of control group (P < 0. 05), and the MCV,MCH,PLT of high dose group was significantly different from that of control group (P < 0. 05). The other results showed no significant difference (P > 0.05). (4) the Cr of ALT,AST, female rats in the middle, middle and high dose groups were significantly different from those in the control group (P < 0. 05). There was a significant difference in TP,ALB between the middle dose group and the control group (P < 0. 05). There was a significant difference in the TP,ALB control group between the middle dose group and the high dose group (P < 0. 05), while the CR in the high dose group was significantly higher than that in the control group (P < 0. 05). The GLU of female and male rats in each group was higher than the normal range. The other results showed no significant difference (P > 0.05). Conclusion: Ruangjian Xiaoying granule is safe to take according to the dosage of test, and has no obvious side effect on blood routine, liver and kidney function of rats. It can be put into the next clinical trial stage.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R285.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 卡咪拉;楊學(xué)智;李海燕;王華敏;牛欣;;自身免疫性甲狀腺炎的針刺干預(yù)作用和四診特征[J];中華中醫(yī)藥雜志;2012年07期

2 紀(jì)孝聯(lián);范琳琳;;中西醫(yī)結(jié)合治療橋本甲狀腺炎40例臨床觀察[J];臨床醫(yī)學(xué);2011年08期

3 張曉輝;國(guó)艷;張建;;五味消毒飲治療橋本甲狀腺炎10例[J];中國(guó)地方病防治雜志;2012年04期

4 姜莉莉;吳軍;張德憲;孫黎明;白春英;曲庚汝;;溫陽(yáng)消癭湯治療慢性淋巴細(xì)胞性甲狀腺炎繼發(fā)甲狀腺功能減退[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2011年06期

5 王莉;唐大軒;熊靜悅;葛麟;王堯;梁婭君;牟道華;譚正懷;;不同月齡SPF級(jí)SD大鼠血液學(xué)及生化指標(biāo)的變化[J];醫(yī)學(xué)動(dòng)物防制;2009年12期

6 劉寶忠;張花;楊坤;吳海燕;廖有喬;;百令膠囊對(duì)橋本甲狀腺炎患者自身免疫性抗體的影響[J];醫(yī)藥導(dǎo)報(bào);2009年06期

7 夏勇;夏鳴U

本文編號(hào)：2342018